AstraZeneca’s Farxiga meets main goal of heart failure study

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

(Reuters) – British drugmaker AstraZeneca Plc said on Tuesday that its diabetes drug Farxiga met the main goal of a late-stage study for the treatment of patients with heart failure.

Farxiga was successful in reducing the risk of cardiovascular death or the worsening of heart failure when used along with the standard treatment in the DAPA-HF trial, the company said in a statement.

Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham

Leave a Reply

Your email address will not be published. Required fields are marked *